Selank and anxiety research: what the Russian studies actually show
A careful read of the literature on a Phase-2 peptide that has not yet earned U.S. clinical credentials.
TL;DR
- Selank is a synthetic peptide developed in Russia in the 1990s and reported there as an anxiolytic — a compound that may reduce anxiety symptoms.
- The published Russian literature suggests effects on GABA tone and BDNF, but trials are small, short, and almost entirely in Russian populations.
- Selank is FDA Category 2 in the United States and is not currently available from 503A compounding pharmacies.
What it is
Selank is a synthetic seven-amino-acid peptide modeled on tuftsin (in plain English: a short fragment of a natural immune-signaling molecule). Picture it as a key cut from a borrowed pattern: the body recognizes the shape because it resembles something it already makes. It was developed at the Russian Academy of Medical Sciences and is marketed there as Selanc, with a clinical indication for generalized anxiety disorder.
How it works
The proposed mechanism is twofold. First, Selank appears to raise GABA activity (in plain English: the brain's main "slow down" signal), producing a calming effect without sedation. Second, animal studies suggest it raises brain-derived neurotrophic factor, or BDNF — a growth factor for brain cells. Think of GABA as the brake pedal and BDNF as fertilizer for the neural network (Kozlovskii et al., Eksp Klin Farmakol, 2007).
Who asks about it
People come to Selank because they have read about a "non-benzodiazepine anti-anxiety peptide" and want to understand whether the research is real or just internet folklore. Many are looking for something that helps anxiety without the sedation or dependency profile of benzodiazepines.
What the research says
The published Russian clinical literature reports anxiolytic and mild antidepressant effects in small open-label and randomized trials, with about 6 in 10 patients in one trial showing symptom reduction over four weeks (Zozulia et al., Zh Nevrol Psikhiatr, 2005). The trials are small (often under 100 patients), short (two to six weeks), and almost entirely conducted in Russian populations. Side effects reported in those studies were minimal — mostly mild headache. Independent replication outside Russia is sparse.
What to know before considering it
Selank is not available from 503A compounding pharmacies in the U.S. while Category 2 status holds. Material sold online as "research use only" is gray-market and unregulated for human use. The Russian literature is suggestive, not definitive. Patients with significant anxiety should work with a clinician on first-line, FDA-approved options.
The Halftime POV
Selank sits in the "interesting but not yet legitimate in the U.S." bucket. We do not prescribe it, do not endorse gray-market sources, and treat the Russian literature as a starting point, not a destination. If Category 1 access returns, Selank deserves a careful U.S. evaluation — small, well-designed trials in well-defined anxiety populations.
Related reading:
- Selank and anxiety: the published research, summarized
- Category 2 peptides: what the classification means
- Semax and cognition: the Russian research
- The February 2026 HHS announcement, explained
FAQ
Q: What is Selank? A: Selank is a synthetic seven-amino-acid peptide based on a fragment of tuftsin, a natural immune molecule. It is studied as an anxiolytic — a compound that may reduce anxiety symptoms — and was developed in Russia in the 1990s.
Q: Is Selank available in the United States? A: Not currently through 503A compounding pharmacies. The FDA classifies Selank as Category 2, which restricts compounding access. A February 2026 HHS announcement proposed returning several peptides to Category 1 pending formal Federal Register notice.
Q: Is Selank FDA-approved? A: No. Selank has never been FDA-approved. The Russian literature reports clinical use in anxiety disorders there, but those studies do not translate to U.S. regulatory approval.
Disclaimer
As of 2026-05-11, several peptides discussed in this article — including Selank — are classified by the FDA as Category 2, which means they are not currently available from 503A compounding pharmacies. A February 2026 HHS announcement proposed returning these peptides to Category 1 pending formal FDA Federal Register notice. This article is educational and is not medical advice. Halftime Health only prescribes through licensed clinicians in states where our partner physicians are credentialed.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
- Selank pharmacology in anxiety models — Eksp Klin Farmakol, 2007
- Selank clinical trial in generalized anxiety — Zh Nevrol Psikhiatr, 2005
This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health's published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What is Selank?
Selank is a synthetic seven-amino-acid peptide based on a fragment of tuftsin, a natural immune molecule. It is studied as an anxiolytic — a compound that may reduce anxiety symptoms — and was developed in Russia in the 1990s.
Is Selank available in the United States?
Not currently through 503A compounding pharmacies. The FDA classifies Selank as Category 2, which restricts compounding access. A February 2026 HHS announcement proposed returning several peptides to Category 1 pending formal Federal Register notice.
Is Selank FDA-approved?
No. Selank has never been FDA-approved. The Russian literature reports clinical use in anxiety disorders there, but those studies do not translate to U.S. regulatory approval.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.